Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
"At the AACR annual meeting, we will present a wide range of preclinical and clinical data that highlights our ability to rapidly and reproducibly interrogate disease biology, design highly selective and potent precision therapies, and advance clinical development to address urgent patient needs," said Fouad Namouni, M.D., President, Research & Development at
The accepted abstract titles are listed below and available on the AACR conference website: https://www.aacr.org/meeting/aacr-annual-meeting-2021/.
Oral Presentation
Presentation Title: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
Session Title: Molecular Targeted Agents in the Clinic
Session Date & Time:
Abstract Number: CT023
Poster Presentations
Presentation Title: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ΔEx19, L858R) and C797S resistance mutations in metastatic NSCLC
Session Title: Novel Antitumor Agents
Session Date & Time:
Abstract Number: 1262
Presentation Title: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date & Time:
Abstract Number: 1467
Presentation Title: Development of a selective CDK2-E inhibitor in CCNE driven cancers
Session Title: Novel Antitumor Agents
Session Date & Time:
Abstract Number: 1279
Presentation Title: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
Session Title: Immunomodulatory Agents and Interventions
Session Date & Time:
Abstract Number: 1717
Presentation Title: Changes in mast cell (MC) numbers and phenotype in patients (pts) with indolent systemic mastocytosis (ISM) treated with avapritinib
Session Title: Phase II Clinical Trials
Session Date & Time:
Abstract Number: CT168
Presentation Title: Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers
Session Title: Phase I Clinical Trials
Session Date & Time:
Abstract Number: CT122
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for
Trademarks
View original content:http://www.prnewswire.com/news-releases/blueprint-medicines-to-showcase-scientific-leadership-in-precision-oncology-and-hematology-at-aacr-annual-meeting-2021-301244983.html
SOURCE
Media Contact : Andrew Law, 617-844-8205, media@blueprintmedicines.com; or Investor Relations Contact, Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com